Value of ALDH1 and CD133 Expression in Predicting the Efficacy of Chemotherapy for Gastric Cancer

OBJECTIVE To explore the value of aldehyde dehydrogenase 1(ALDH1) protein and cluster of differentiation 133(CD133) protein expression in predicting the efficacy of chemotherapy for gastric cancer. METHODS Immunohistochemical method was used to detect the expression of ALDH1 protein and CD133 protein in 81 patients with gastric cancer who underwent oxaliplatin-based chemotherapy from March 2018 to May 2019 at Hengshui People's Hospital. CT evaluated the efficacy of chemotherapy, analyzed the relationship between clinicopathological features and chemotherapy efficacy. RESULTS There were 28 cases of progressive disease(PD) in 81 cases of gastric cancer, 38 cases of stable disease(SD), 13 cases of partial response(PR), 2 cases of complete response(CR). The yield of total chemotherapy(SD+PR+CR) was 65.4%. Univariate analysis showed that patients with ALDH1 protein positive, CD133 protein positive expression and poor differentiation had poorer chemotherapy efficacy(P<0.05). Gender, age, lesion location, clinical stage and lymph node metastasis were not significantly correlated with chemotherapy efficacy of gastric cancer. Multivariate analysis showed that ALDH1 protein and CD133 protein expression were independent predictors of poor chemotherapy response in patients with advanced gastric cancer. CONCLUSION The positive expression of ALDH1 protein and CD133 protein may be an important molecular biological indicator for predicting the efficacy gastric cancer, which may provide a reference for individualized treatment of gastric cancer.